ENTHEON BIOMEDICAL CORP News

ENTHEON BIOMEDICAL CORP To Carry Out 1-for-10 Reverse Stock Split On March 1st, 2024

February 29th - $ENTHEON BIOMEDICAL CORP(ENTBF.US)$ is about to implement a 1-for-10 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from March 1st, 2024.$ENTHEO

moomoo NewsFeb 28 19:40 ET

RBC Downgrades Nevro to Sector Perform, Cites Salesforce Turnaround

Seeking AlphaJan 12 11:01 ET

Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill

Want to get the latest psychedelics industry news in your inbox every week? Subscribe to our Newsletter to become a Psychedelics Insider. Numinus (OTC:NUMIF) concluded its acquisition of Novamind (OTC

Benzinga Real-time NewsJun 15, 2022 12:34 ET

Largest Phase-1 DMT Study In The Netherlands, A Collaboration Between Entheon & Cybin

Cybin Inc. (NEO:CYBN) (NYSE:CYBE) announced that, through its wholly-owned subsidiary Cybin IRL Limited, It has entered into an agreement to acquire a Phase 1 N,N-dimethyltryptamine ("DMT") study from

Benzinga Real-time NewsJun 7, 2022 17:10 ET

Cybin to acquire DMT clinical study from Entheon Biomedical

Cybin (NYSE:CYBN) added ~8% in the pre-market Tuesday after the psychedelics-focused biopharma announced that its subsidiary Cybin IRL Limited agreed to acquire a Phase 1 N,N-dimethyltryptamine ("DMT"

Seeking AlphaJun 7, 2022 08:28 ET

Ehave Partners With Halugen Life Sciences To Create A Ketamine Precision Medicine Platform For Clinical Research

Ehave, Inc. (OTC:EHVVF) is a leading healthcare services and technology company focused on progressing psychedelics to therapeutics by engineering novel compounds and new treatment protocols for treat

Benzinga Real-time NewsJun 1, 2022 16:30 ET

Entheon Biomedical Announces Non-Brokered Private Placement Financing

Entheon Biomedical Corp. (OTCQB:ENTBF) announced a non-brokered private placement financing for up to 30,000,000 Units at a price of CDN$0.10 per unit, for gross proceeds of up to CDN$3,000,000. Each

Benzinga Real-time NewsApr 5, 2022 15:46 ET

Entheon Biomedical begins enrollment in phase 1 study of DMT for addiction disorders

Entheon Biomedical (OTCQB:ENTBF) said the first patient was enrolled in a phase 1 trial called EBRX-101 evaluating N, N-dimethyltryptamine (DMT) for addiction disorders. In the study — which is being

Seeking AlphaMar 15, 2022 11:06 ET

Entheon Biomedical gets recruitment underway in EBIQ-101 ketamine study

Entheon Biomedical (OTCQB:ENTBF) announces that recruitment has begun for the clinical research study with Heading Health to determine the electro-neurophysiologic effects of ketamine. EBIQ-101, an O

Seeking AlphaNov 10, 2021 08:41 ET

Entheon Biomedical Acquires Lobo Genetics, Inc. in Bid to Strengthen Screening and Treatment Evaluation Tech for Psychedelics

Image Provided by Wiki Commons Entheon Biomedical Corp. (OTCQB:ENTBF), the biotech research and development company focused on developing DMT-based treatments for addiction and substance use disorders

Benzinga Real-time NewsOct 6, 2021 09:24 ET

Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform

Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq debut on Friday. The Berlin-based company is joining an exclusive group of start-ups in the psychedelics sector to IPO this year o

Benzinga Real-time NewsJun 21, 2021 10:21 ET